0001078274-21-000006.txt : 20211210
0001078274-21-000006.hdr.sgml : 20211210
20211210170359
ACCESSION NUMBER: 0001078274-21-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211208
FILED AS OF DATE: 20211210
DATE AS OF CHANGE: 20211210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MYERS STEVEN S
CENTRAL INDEX KEY: 0001078274
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33650
FILM NUMBER: 211486116
MAIL ADDRESS:
STREET 1: 4695 MACAUTHUR COURT
STREET 2: EIGHTH FLOOR
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
FORMER NAME:
FORMER CONFORMED NAME: MEYERS STEVEN S
DATE OF NAME CHANGE: 19990203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CALADRIUS BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0000320017
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
IRS NUMBER: 222343568
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 110 ALLEN ROAD
STREET 2: SECOND FLOOR
CITY: BASKING RIDGE
STATE: NJ
ZIP: 07920
BUSINESS PHONE: 908-842-0100
MAIL ADDRESS:
STREET 1: 110 ALLEN ROAD
STREET 2: SECOND FLOOR
CITY: BASKING RIDGE
STATE: NJ
ZIP: 07920
FORMER COMPANY:
FORMER CONFORMED NAME: Caladrius Biosciences, Inc.
DATE OF NAME CHANGE: 20150608
FORMER COMPANY:
FORMER CONFORMED NAME: NeoStem, Inc.
DATE OF NAME CHANGE: 20060906
FORMER COMPANY:
FORMER CONFORMED NAME: PHASE III MEDICAL INC/DE
DATE OF NAME CHANGE: 20030819
4
1
wf-form4_163917382551212.xml
FORM 4
X0306
4
2021-12-08
0
0000320017
CALADRIUS BIOSCIENCES, INC.
CLBS
0001078274
MYERS STEVEN S
C/O CALADRIUS BIOSCIENCES, INC.
110 ALLEN ROAD, 2ND FLOOR
BASKING RIDGE
NJ
07920
1
0
0
0
Common Stock
2021-12-08
4
P
0
33785
0.8936
A
146839
D
Common Stock
8434
I
By Steven S Myers IRA
Common Stock
1954
I
By Steven S Myers Revocable Trust dated 12/1/2000
Common Stock
802
I
By spouse
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8802 to $0.9000, inclusive. The reporting person undertakes to provide Caladrius Biosciences, Inc., any security holder of Caladrius Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Represents 37,735 unvested restricted stock awards granted under Issuer's 2018 Equity Incentive Compensation plan, which will vest on January 11, 2022.
Steven S. Myers, By: /s/ Todd C. Girolamo, Esq., Attorney-in-Fact
2021-12-10